Tsumura & Co. (TYO:4540)
3,822.00
-28.00 (-0.73%)
At close: Dec 5, 2025
Tsumura & Co. Revenue
Tsumura & Co. had revenue of 46.80B JPY in the quarter ending September 30, 2025, with 3.13% growth. This brings the company's revenue in the last twelve months to 181.92B, up 10.51% year-over-year. In the fiscal year ending March 31, 2025, Tsumura & Co. had annual revenue of 181.09B with 20.05% growth.
Revenue (ttm)
181.92B
Revenue Growth
+10.51%
P/S Ratio
1.56
Revenue / Employee
42.58M
Employees
4,272
Market Cap
284.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 181.09B | 30.25B | 20.05% |
| Mar 31, 2024 | 150.85B | 10.80B | 7.71% |
| Mar 31, 2023 | 140.04B | 10.50B | 8.10% |
| Mar 31, 2022 | 129.55B | -1.34B | -1.02% |
| Mar 31, 2021 | 130.88B | 7.64B | 6.19% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,213.71B |
| HOYA Corporation | 892.50B |
| Takeda Pharmaceutical Company | 4,417.00B |
| Daiichi Sankyo Company | 1,978.88B |
| Otsuka Holdings | 2,418.53B |
| Astellas Pharma | 2,006.82B |
| Terumo | 1,062.42B |
| Shionogi & | 437.26B |